Godínez V, Garibay M, Mirabent F, Pérez CA

Language: Spanish
References: 13
Page: 302-307
PDF size: 58.13 Kb.

ABSTRACT

Objective: To evaluate the effectiveness of the combination of ketoconazol 400 mg + clindamycin 100 mg for 6 days compared to ketoconazol 800 mg + clindamycin 100 mg in Candida vaginitis and bacterial vaginosis.
Material and methods: Patients aged 18-60 years, with clinical diagnosis of Candida vaginitis and vaginosis confirmed by culture of genital secretions were included. Patients were assigned at random to one of two treatment groups: group 1 was given ketoconazol 400 mg + clindamycin 100 mg during six days (K/C6D); group 2 received ketoconazol 800 mg + clindamycin 100 mg for three days + placebo during three days (K/C3D). Patients were evaluated at days 7 and 11 after initiating treatment, at day 11 culture of vaginal secretion was repeated; along with treatment and follow up period patients were asked to report presence of adverse events.
Results: Eighty-two patients were included, 41 in K/C6D group and 40 in K/C3D group. C. albicans was found at baseline in 19 patients in K/C6D group and in 15 in K/C3D group; at day 11 was cultured in 2/19 patients (10.52%) and in 2/15 (13.33%) (p = 0.626) respectively; G. vaginalis was cultured at baseline in 25 patients of each group, at day 11 was cultured in 1/25 patients (4.0%) of K/C6D group and in 4/25 (16.0%) of K/C3D group (p = 0.174). Clinical cure was found in 36/41 cases (87.8%) of K/C6D group and in 34/40 cases (85.00%) of K/C3D (p = 0.965) group. Only five patients presented adverse events, of which three were related to the treatment.
Conclusion: Treatment of vaginitis and bacterial vaginosis with anyone of both formulations has the same clinical and microbiological effectiveness, and is well tolerated by the patient. The fact that K/C3D formulation is as effective as K/C6D has the advantage of shortening the treatment time of vaginal infections, and allows a better patient compliance.

REFERENCES

1. Gómez Bravo TE, Garibay VM. Evaluación de la eficacia de la combinación de ketoconazol/clindamicina comparado con metronidazol/nistatina en vaginitis candidiásica y vaginosis bacteriana. Ginecol Obstet Mex 2004,72:575-80.

2. Sobel J, Peipert JF, McGregor JA, et al. Efficacy of clindamycin vaginal ovule (3-day treatment) vs clindamycin vaginal cream (7-day treatment) in bacterial vaginosis. Infect Dis Obstet Gynecol 2001;91:9-15.

3. Paavonen J, Mangioni C, Martin MA, et al. Bacterial vaginosis cure rates were similar with clindamycin vaginal ovules for 3 days and oral metronidazole for 7 days. Obstet Gynecol 2000;96:256-60.

4. Gerhard I, Ohlhorst D, Eggert-Kruse W, et al., Topical one-day treatment with ketoconazole: a double-blind randomized control study on vaginal candidosis. Mycoses 1989;32(5):253-65.

5. Creatsas G, Zissis NP, Lolis D. Ketoconazole, a new antifungal agent in vaginal candidiasis. Curr Ther Res Clin Exp 1980;28 (1):121-6.

6. Smith EB, Henry JC. Ketoconazole: an orally effective antifungal agent. Mechanism of action, pharmacology, clinical efficacy and adverse effects. Pharmacotherapy 1984;4(4): 199-204.

7. Ene MD, Williamson PJ, Daneshmend TK, et al. Systemic absorption of ketoconazole from vaginal pessaries. Br J Clin Pharmacol 1984;17(2):173-5.

8. Amsel R, Totten PA, Spiegel CA, et al. Non specific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med 1983;74:14-22.

9. Sereno CJA, Ricalde BC, de la Cabada J, et al. Frecuencia de diferentes patógenos como causa de vaginitis en México. Ginecol Obstet Mex 1990;58:128-32.

10. Hardman G, Limbird E, et al. Goodman y Gilman. Bases farmacológicas de la terapéutica. 9a ed. México: McGraw-Hill Interamericana, 1996;p:2.

11. Muñoz RJ, et al. Eficacia y tolerancia de 200 mg de fenticonazol vs 400 mg de miconazol en el tratamiento de vulvovaginitis micótica. Ginecol Obstet Mex 2002;70:59-65.

12. Consumano AL, Costa AL, Veroneses M. Bacterial vaginosis cured in three days with new cleocin vaginal ovule. Doctors Guide 1998;5:135.

13. Broumas AG, Basara CA. Potential patient preference for 3-day treatment of bacterial vaginosis; responses to new suppository from of clindamycin. Adv Ther 2000;17(3):159-66.